Edesa Biotech, Inc. (EDSA) Stock Forecast
EDSA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $16.33 average of analyst targets
- Upside to target
- +535.5% from the latest close
- Next earnings
- —
- 52-week range
- $0.80 – $18.28
EDSA analyst ratings
2 analystsNumber of analysts at each rating.
EDSA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EDSA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (FY2026) | −$1.99 | −$1.99 | −$1.98 | −$1.27 | −56.4% | 3 |
| Next fiscal year (FY2027) | −$2.07 | −$2.46 | −$1.46 | −$1.99 | −4.0% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EDSA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Dec '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (FY2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (FY2027) | $0 | $0 | $0 | 0.0% | 3 |
EDSA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EDSA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (FY2026) | −$1.57 | −$1.57 | −$1.66 | −$1.99 | −$1.99 | +26.5% | 0 up · 2 down |
| Next fiscal year (FY2027) | −$1.96 | −$1.96 | −$2.01 | −$1.96 | −$2.07 | +5.4% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EDSA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; EDSA beat in 8 of 12.
What analysts expect from EDSA
2 analysts cover Edesa Biotech; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $16.33, 535.5% above the latest close of $2.57. Analysts expect earnings of −$1.99 per share for FY2026, −56.4% from a year earlier. For FY2027 the average estimate is −$2.07 per share. Edesa Biotech beat the EPS estimate in 8 of the last 12 quarters.
Related: EDSA income statement, EDSA key metrics, EDSA chart. See the EDSA stock overview for the latest quote and news.
EDSA forecast FAQ
What is Edesa Biotech's price target?
The average analyst price target for Edesa Biotech is $16.33, 535.5% above the latest close of $2.57.
Is Edesa Biotech a buy, hold or sell?
Of 2 analysts covering Edesa Biotech, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Edesa Biotech's EPS forecast?
Analysts forecast −$1.99 per share for FY2026 (range −$1.99 to −$1.98); for FY2027 the estimate is −$2.07.
Does Edesa Biotech usually beat earnings estimates?
Edesa Biotech reported EPS at or above the analyst estimate in 8 of the last 12 quarters.